Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470.

Medical and pediatric oncology Pub Date : 2000-12-01 DOI:10.1002/1096-911x(20001201)35:6<673::aid-mpo41>3.0.co;2-o

S Shusterman, S A Grupp, J M Maris

{"title":"Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470.","authors":"S Shusterman, S A Grupp, J M Maris","doi":"10.1002/1096-911x(20001201)35:6<673::aid-mpo41>3.0.co;2-o","DOIUrl":null,"url":null,"abstract":"Unlabelled: Background and Procedure High-risk neuroblastoma disease features are correlated with tumor vascularity, suggesting that angiogenesis inhibitors may be a useful addition to current therapeutic strategies. We therefore examined the efficacy of TNP-470 (TAP Pharmaceuticals, Deerfield, IL) in human neuroblastoma xenograft models.Results: Tumor growth rate was markedly inhibited in mice receiving TNP-470 administered alone with a treatment to control ratio (T/C) at day 21 = 0.4 (P <.001). TNP-470 also significantly inhibited tumorigenicity when administered shortly after xenograft inoculation (T/C at day 30 = 0.1, P <.001) and when administered following cyclophosphamide (T/C at day 35 = 0.1, P <.001).Conclusions: These data show that TNP-470 is a potent inhibitor of human neuroblastoma growth both alone and when given with conventional chemotherapy, suggesting that it may be a useful adjunctive therapy for high-risk neuroblastoma patients.","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"35 6","pages":"673-6"},"PeriodicalIF":0.0000,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<673::aid-mpo41>3.0.co;2-o","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical and pediatric oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/1096-911x(20001201)35:6<673::aid-mpo41>3.0.co;2-o","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 22

Abstract

Unlabelled: Background and Procedure High-risk neuroblastoma disease features are correlated with tumor vascularity, suggesting that angiogenesis inhibitors may be a useful addition to current therapeutic strategies. We therefore examined the efficacy of TNP-470 (TAP Pharmaceuticals, Deerfield, IL) in human neuroblastoma xenograft models.

Results: Tumor growth rate was markedly inhibited in mice receiving TNP-470 administered alone with a treatment to control ratio (T/C) at day 21 = 0.4 (P <.001). TNP-470 also significantly inhibited tumorigenicity when administered shortly after xenograft inoculation (T/C at day 30 = 0.1, P <.001) and when administered following cyclophosphamide (T/C at day 35 = 0.1, P <.001).

Conclusions: These data show that TNP-470 is a potent inhibitor of human neuroblastoma growth both alone and when given with conventional chemotherapy, suggesting that it may be a useful adjunctive therapy for high-risk neuroblastoma patients.

查看原文本刊更多论文

TNP-470对人神经母细胞瘤异种移植模型肿瘤生长的抑制作用。

高危神经母细胞瘤疾病特征与肿瘤血管性相关，提示血管生成抑制剂可能是当前治疗策略的有用补充。因此，我们检测了TNP-470 (TAP Pharmaceuticals, Deerfield, IL)在人类神经母细胞瘤异种移植模型中的疗效。结果:在第21天，TNP-470与治疗对照比(T/C) = 0.4时，小鼠肿瘤生长速度明显受到抑制(P)。结论:这些数据表明，无论是单独给药还是与常规化疗一起给药，TNP-470都是一种有效的人类神经母细胞瘤生长抑制剂，提示TNP-470可能是一种有用的高风险神经母细胞瘤患者的辅助治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical and pediatric oncology

自引率

0.00%

发文量